The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Open accessAbstract
CRISPR RNA-guided nucleases (RGNs) are widely used genome-editing reagents, but methods to delineate their genome-wide, off-target cleavage activities have been lacking. Here we describe an approach for global detection of DNA double-stranded breaks (DSBs) introduced by RGNs and potentially other nucleases. This method, called genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq), relies on capture of double-stranded oligodeoxynucleotides into DSBs. Application of GUIDE-seq to 13 RGNs in two human cell lines revealed wide variability in RGN off-target activities and unappreciated characteristics of off-target sequences. The majority of identified sites were not detected by existing computational methods or chromatin immunoprecipitation sequencing (ChIP-seq). GUIDE-seq also identified RGN-independent genomic breakpoint 'hotspots'. Finally, GUIDE-seq revealed that truncated guide RNAs exhibit substantially reduced RGN-induced, off-target DSBs. Our experiments define the most rigorous framework for genome-wide identification of RGN off-target effects to date and provide a method for evaluating the safety of these nucleases before clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A primary limitation of GUIDE-seq is relevant to the low delivery efficiency of dsODNs into cells, which results in detection of only 30%–50% of all the DSBs (Tsai et al., 2015; Pan et al., 2022).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Off-target profiling of AsCas12a-crRNA+11 genome editing in HEK293/3272-26A>G cells18,42 showed very high specificity, as demonstrated by exclusive editing of the 3272-26A>G CFTR locus, while non-specific cleavages in the second allele, or any other genomic loci, could not be detected (Fig. 2c and Supplementary Fig. 4c).”
From Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing (2019) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While cleavage at sites with perfect complementarity to the protospacer domain of the gRNA typically occurs with highest efficiency, cleavage at sites having one to several bases of mismatch with the gRNA can occur. These undesired cleavage events are called “off-target effects” (OTEs)10, and their existence should be minimized for therapeutic applications of genome editing technologies.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The GUIDE-seq procedure10 can be used to empirically identify real off-target sites in cells.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“GUIDE-seq can detect off-target sites with indel frequencies as low as 0.03% (Tsai et al., 2015).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“GUIDE-seq is more sensitive than the IDLV method because dsODNs integrate more efficiently and precisely into DSBs, while the integration events of IDLV is low in number and can distribute as far as 500bp away from the actual DSB sites (Tsai et al., 2015; Cromer et al., 2023).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“However, other publications observed a much lower validation rate (Cencic et al., 2014; Duan et al., 2014; Tsai et al., 2015).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“These studies indicated that Cas9 could associate with genomic loci without exerting its nuclease function, deposing a major caveat in Cas9 ChIP-Seq-based off-target detection assay.”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, compared to cell-based methods such as GUIDE-seq (see next section) (Tsai et al., 2015), Extru-seq exhibited much lower false negative rate (2.3% versus 29%) (Kwon et al., 2023).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
In the citing paper
“Using the standard Guide-seq protocol, we detected only the Fah target site and one off-target site (defined as Guide-seq off-target site 1, or GOT1) (Supplementary Data Set 1).”
From Adenine base editing in an adult mouse model of tyrosinaemia (2019) · cites this paper as [23]
In the citing paper
“However, silicon methods can only identify part of the off-target cleavage.48”
From CRISPR-Cas9: a new and promising player in gene therapy (2015) · cites this paper as [48]
In the citing paper
“The major barrier of clinical use of CRISPR/Cas9 is its off-target effects [81,82,83].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citationCRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Self-citationRNA-guided editing of bacterial genomes using CRISPR-Cas systems
Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2508 · Cited by 2,429
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,009
Development of aptamer-based inhibitors for CRISPR/Cas system
Zhao, J. C., Inomata, R., Kato, Y., & Miyagishi, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa865 · Cited by 31
Gray, D., Villegas, I. J., Long, J. D., Santos, J., Keir, A., Abele, A. N., Kuo, C. Y., & Kohn, D. B. (2021) · The CRISPR Journal · doi:10.1089/crispr.2020.0080 · Cited by 34
The Off-Targets of Clustered Regularly Interspaced Short Palindromic Repeats Gene Editing
Vicente, M. M., Chaves‐Ferreira, M., Jorge, J. M. P., Proença, J. T., & Barreto, V. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.718466 · Cited by 31
Exploiting the CRISPR/Cas9 PAM Constraint for Single-Nucleotide Resolution Interventions
Li, Y., Mendiratta, S., Ehrhardt, K., Kashyap, N., White, M. A., & Bleris, L. G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0144970 · Cited by 31
Data imbalance in CRISPR off-target prediction
Gao, Y., Chuai, G., Yu, W., Qu, S., & Liu, Q. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz069 · Cited by 31
CRISPR therapy towards an HIV cure
Herrera-Carrillo, E., Gao, Z., & Berkhout, B. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz021 · Cited by 31
Genome and base editing for genetic hearing loss
Niggemann, P., György, B., & Chen, Z. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107958 · Cited by 32
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 32
Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel
Yen, A., Zappala, Z., Fine, R. S., Majarian, T. D., Sripakdeevong, P., & Altshuler, D. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2313119 · Cited by 30
Harnessing noncanonical crRNA for highly efficient genome editing
Xun, G., Zhu, Z., Singh, N., Lu, J., Jain, P., & Zhao, H. (2024) · Nature Communications · doi:10.1038/s41467-024-48012-x · Cited by 33
Tang, S., Chen, X., Tong, X., & Zhu, L. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.112724 · Cited by 31
The Rise of CRISPR/Cas for Genome Editing in Stem Cells
Shui, B., Hernández-Matías, L., Guo, Y., & Peng, Y. (2016) · Stem Cells International · doi:10.1155/2016/8140168 · Cited by 33
Genome Engineering with TALE and CRISPR Systems in Neuroscience
Lee, H. B., Sundberg, B. N., Sigafoos, A. N., & Clark, K. J. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00047 · Cited by 33
Engineered CRISPR Systems for Next Generation Gene Therapies
Pineda, M., Moghadam, F., Ebrahimkhani, M. R., & Kiani, S. (2017) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00011 · Cited by 30
Genetically engineered mouse models for studying radiation biology
Castle, K. D., Chen, M., Wisdom, A. J., & Kirsch, D. G. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.06.19 · Cited by 32
Orthogonal Cas9–Cas9 chimeras provide a versatile platform for genome editing
Bolukbasi, M. F., Liu, P., Luk, K., Kwok, S. F., Gupta, A., Amrani, N., Sontheimer, E. J., Zhu, L. J., & Wolfe, S. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07310-x · Cited by 30
Herai, R. H. (2019) · Gene · doi:10.1016/j.gene.2019.03.019 · Cited by 30
Başar, R., Daher, M., Uprety, N., Gokdemir, E., Alsuliman, A., Ensley, E. L., Ozcan, G., Mendt, M. C., Sanabria, M. H., Kerbauy, L. N., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001977 · Cited by 31
The evolution and history of gene editing technologies
Randhawa, S., & Sengar, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.002 · Cited by 31
Kurgan, G., Turk, R., Li, H., Roberts, N., Rettig, G. R., Jacobi, A. M., Tso, L., Sturgeon, M. L., Mertens, M., Noten, R., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.024 · Cited by 31
High-throughput methods for genome editing: the more the better
Huang, Y., Shang, M., Liu, T., & Wang, K. (2022) · PLANT PHYSIOLOGY · doi:10.1093/plphys/kiac017 · Cited by 32
Kotmayer, L., Romero–Moya, D., Marín-Béjar, O., Kozyra, E. J., Català, A., Bigas, A., Włodarski, M. W., Bödör, C., & Giorgetti, A. (2022) · British Journal of Haematology · doi:10.1111/bjh.18330 · Cited by 31
Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies
Paschoudi, K., Yannaki, E., & Psatha, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119527 · Cited by 30
Hough, S. H., Kancleris, K., Brody, L., Humphryes-Kirilov, N., Wolanski, J., Dunaway, K. W., Ajetunmobi, A., & Dillard, V. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1581-4 · Cited by 30
CRISPR deletion of MIEN1 in breast cancer cells
Treuren, T. V., & Vishwanatha, J. K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204976 · Cited by 30
Linking CRISPR–Cas9 double-strand break profiles to gene editing precision with BreakTag
Longo, G. M. C., Sayols, S., Kotini, A. G., Heinen, S., Möckel, M. M., Beli, P., & Roukos, V. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02238-8 · Cited by 32
Engineering a New Generation of Gene Editors: Integrating Synthetic Biology and AI Innovations
Chia, B. S., Seah, S., Wang, B., Shen, K., Srivastava, D., & Chew, W. L. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00686 · Cited by 31
CRISPR Diagnosis and Therapeutics with Single Base Pair Precision
Lee, S. H., Park, Y., Jin, Y. B., Kim, S., & Hur, J. K. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.09.008 · Cited by 29
Sullivan, N. T., Dampier, W., Chung, C.-H., Allen, A. G., Atkins, A., Pirrone, V., Homan, G., Passic, S. R., Williams, J. W., Zhong, W., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52353-9 · Cited by 32
History, evolution and classification of CRISPR-Cas associated systems
Agarwal, N., & Gupta, R. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.12.012 · Cited by 29
Shui, S., Wang, S., & Liu, J. (2022) · Bioengineering · doi:10.3390/bioengineering9020083 · Cited by 29
Controlling CRISPR‐Cas9 by guide RNA engineering
Hu, L., Li, Y., Wang, J., Zhao, Y., & Wang, Y. (2022) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1731 · Cited by 31
Dashnau, J. L., Xue, Q., Nelson, M., Law, E., Cao, L., & Hei, D. J. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.08.001 · Cited by 30
Meng, H., Nan, M., Li, Y., Ding, Y., Yin, Y., & Zhang, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1148412 · Cited by 31
Gene editing and its application for hematological diseases
Osborn, M. J., Belanto, J. J., Tolar, J., & Voytas, D. F. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2017-z · Cited by 32
Off the shelf T cell therapies for hematologic malignancies
McCreedy, B. J., Senyukov, V., & Nguyen, K. T. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.03.001 · Cited by 31
Off- and on-target effects of genome editing in mouse embryos
Ayabe, S., NAKASHIMA, K., & Yoshiki, A. (2018) · Journal of Reproduction and Development · doi:10.1262/jrd.2018-128 · Cited by 31
CRISPys: Optimal sgRNA Design for Editing Multiple Members of a Gene Family Using the CRISPR System
Hyams, G., Abadi, S., Lahav, S., Avni, A., Halperin, E., Shani, E., & Mayrose, I. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.03.019 · Cited by 31
Wu, Y., Liu, Y., Lv, X., Li, J., Du, G., & Liu, L. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00349 · Cited by 29
Identifying Novel Enhancer Elements with CRISPR-Based Screens
Klein, J. C., Chen, W., Gasperini, M. J., & Shendure, J. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00778 · Cited by 33
Ji, R.-J., Cao, G.-H., Zhao, W., Wang, M.-Y., Gao, P., Zhang, Y.-Z., Wang, X.-B., Qiu, H.-Y., Chen, D.-D., Tong, X.-H., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.09.003 · Cited by 30
Jiang, Y., Chen, S., Hsiao, S., Zhang, H., Xie, D., Wang, Z. J., Ren, W., Liu, M., Liao, J., & Wu, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.003 · Cited by 28
CRISPR-dependent base editing as a therapeutic strategy for rare monogenic disorders
Cabré-Romans, J.-J., & Cuella-Martin, R. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1553590 · Cited by 33
CRISPR-based therapeutic genome editing for inherited blood disorders
Levesque, S., & Bauer, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01236-y · Cited by 31
CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy
Zhang, X., Wang, L., Liu, M., & Li, D. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9057-2 · Cited by 28
Trinucleotide repeat instability during double-strand break repair: from mechanisms to gene therapy
Mosbach, V., Poggi, L., & Richard, G. (2018) · Current Genetics · doi:10.1007/s00294-018-0865-1 · Cited by 28
CRISPR Craze to Transform Cardiac Biology
van Kampen, S. J., & van Rooij, E. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.06.008 · Cited by 30
DNA Double Strand Breaks and Chromosomal Translocations Induced by DNA Topoisomerase II
Gómez-Herreros, F. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00141 · Cited by 32
Gene Editing Correction of a Urea Cycle Defect in Organoid Stem Cell Derived Hepatocyte-like Cells
Zabulica, M., Jakobsson, T., Ravaioli, F., Vosough, M., Gramignoli, R., Ellis, E. C. S., Rooyackers, O., & Strom, S. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031217 · Cited by 29
On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis
Ensinck, M. M., Mottais, A., Detry, C., Leal, T., & Carlon, M. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.662110 · Cited by 31
New Frontiers: Precise Editing of Allergen Genes Using CRISPR
Brackett, N. F., Pomés, A., & Chapman, M. D. (2022) · Frontiers in Allergy · doi:10.3389/falgy.2021.821107 · Cited by 29
Modeling and correction of structural variations in patient-derived iPSCs using CRISPR/Cas9
Park, C., Sung, J. J., Choi, S.-H., Lee, D. R., Park, I., & Kim, D. (2016) · Nature Protocols · doi:10.1038/nprot.2016.129 · Cited by 28
CRISPR-Cas9: From a bacterial immune system to genome-edited human cells in clinical trials
Kick, L. M., Kirchner, M., & Schneider, S. (2017) · Bioengineered · doi:10.1080/21655979.2017.1299834 · Cited by 32
Gene editing prospects for treating inherited retinal diseases
Benati, D., Patrizi, C., & Recchia, A. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106473 · Cited by 28
When genome editing goes off-target
Kempton, H. R., & Qi, L. S. (2019) · Science · doi:10.1126/science.aax1827 · Cited by 30
CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders
Hussen, B. M., Najmadden, Z. B., Abdullah, S. R., Rasul, M. F., Mustafa, S. A., Ghafouri‐Fard, S., & Taheri, M. N. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01713-8 · Cited by 28
Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders
Li, M., Lin, Y., Cheng, Q., & Wei, T. (2025) · Cell Proliferation · doi:10.1111/cpr.13808 · Cited by 28
Novel Thrombotic Function of a Human SNP in STXBP5 Revealed by CRISPR/Cas9 Gene Editing in Mice
Zhu, Q. M., Ko, K. A., Ture, S. K., Mastrangelo, M. A., Chen, M., Johnson, A. D., O’Donnell, C. J., Morrell, C. N., Miano, J. M., & Lowenstein, C. J. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308614 · Cited by 27
Christie, K. A., Robertson, L. J., Conway, C., Blighe, K., DeDionisio, L., Chao-Shern, C., Kowalczyk, A. M., Marshall, J., Turnbull, D. M., Nesbit, M. A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.002 · Cited by 27
Köcher, T., Bischof, J., Haas, S. A., March, O. P., Liemberger, B., Hainzl, S., Illmer, J., Hoog, A., Muigg, K., Binder, H., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.05.015 · Cited by 27
Huang, H., Hu, Y., Huang, G., Ma, S., Feng, J., Wang, D., Lin, Y., Zhou, J., & Rong, Z. (2021) · Communications Biology · doi:10.1038/s42003-021-02351-3 · Cited by 28
Prime editing: current advances and therapeutic opportunities in human diseases
Fu, Y., He, X., Gao, X. D., Li, F., Ge, S., Yang, Z. H., & Fan, X. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.11.015 · Cited by 28
Progress in the application of CRISPR: From gene to base editing
Wu, W., Yang, Y., & Lei, H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21537 · Cited by 28
Advances in the gene therapy of monogenic blood cell diseases
Bueren, J. A., Bustamante, O. Q., Almarza, E., Navarro, S., Rı́o, P., Segovia, J. C., & Güenechea, G. (2019) · Clinical Genetics · doi:10.1111/cge.13593 · Cited by 28
Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches
Lamsfus‐Calle, A., Daniel-Moreno, A., Ureña-Bailén, G., Raju, J., Antony, J. S., Handgretinger, R., & Mezger, M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100641 · Cited by 29
Engineering guide RNA to reduce the off-target effects of CRISPR
Wu, J., & Yin, H. (2019) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.11.003 · Cited by 28
Innovative Precision Gene‐Editing Tools in Personalized Cancer Medicine
Dai, X., Blancafort, P., Wang, P., Sgro, A., Thompson, E. W., & Ostrikov, K. (2020) · Advanced Science · doi:10.1002/advs.201902552 · Cited by 28
Development of multiplexed orthogonal base editor (MOBE) systems
Cowan, Q. T., Gu, S., Gu, W., Ranzau, B. L., Simonson, T. S., & Komor, A. C. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02240-0 · Cited by 26
Meng, X., Jia, R., Zhao, X., Zhang, F., Chen, S., Yu, S., Liu, X., Dou, H., Feng, X., Zhang, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48092-9 · Cited by 28
Steyer, B., Carlson-Stevermer, J., Angenent-Mari, N., Khalil, A. S., Harkness, T., & Saha, K. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.12.036 · Cited by 28
Rapid and efficient analysis of gene function using CRISPR ‐Cas9 in Xenopus tropicalis founders
Shigeta, M., Sakane, Y., Iida, M., Suzuki, M., Kashiwagi, K., Kashiwagi, A., Fujii, S., Yamamoto, T., & Suzuki, K. (2016) · Genes to Cells · doi:10.1111/gtc.12379 · Cited by 26
Genome Engineering for Osteoarthritis: From Designer Cells to Disease-Modifying Drugs
Choi, Y.-R., Collins, K., Lee, J.-W., Kang, H., & Guilak, F. (2019) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-018-0172-4 · Cited by 25
Optical Manipulation of CRISPR/Cas9 Functions: From Ultraviolet to Near-Infrared Light
Chen, Y., Yan, X., & Yuan, P. (2020) · ACS Materials Letters · doi:10.1021/acsmaterialslett.0c00041 · Cited by 26
Bar-seq strategies for the LeishGEdit toolbox
Beneke, T., & Gluenz, E. (2020) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2020.111295 · Cited by 26
Aljanahi, A. A., Lazzarotto, C. R., Chen, S., Shin, T., Cordes, S., Fan, X., Jabara, I., Zhou, Y., Young, D. J., Lee, B., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.016 · Cited by 27
Self-citationWang, L., Wang, Y., Makhmoudova, A., Nitschké, F., Tetlow, I. J., & Emes, M. J. (2021) · PLANT PHYSIOLOGY · doi:10.1093/plphys/kiab535 · Cited by 26
How to Completely Squeeze a Fungus—Advanced Genome Mining Tools for Novel Bioactive Substances
Schüller, A., Studt, L., & Strauss, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091837 · Cited by 26
Principles of Zebrafish Nephron Segment Development
Nguyen, T. K., Petrikas, M., Chambers, B. E., & Wingert, R. A. (2023) · Journal of Developmental Biology · doi:10.3390/jdb11010014 · Cited by 26
Uncovering the dynamics of precise repair at CRISPR/Cas9-induced double-strand breaks
Ben‐Tov, D., Mafessoni, F., Cucuy, A., Honig, A., Melamed‐Bessudo, C., & Levy, A. A. (2024) · Nature Communications · doi:10.1038/s41467-024-49410-x · Cited by 27
Markossian, S., Guyot, R., Richard, S., Teixeira, M., Aguilera, N., Bouchet, M., Plateroti, M., Guan, W., Gauthier, K. C., Aubert, D., et al. (2017) · Thyroid · doi:10.1089/thy.2017.0389 · Cited by 26
Russo, M. T., Cigliano, R. A., Sanseverino, W., & Ferrante, M. I. (2018) · PeerJ · doi:10.7717/peerj.5507 · Cited by 26
Kim, K.-T., Park, J.-C., Jang, H., Lee, H., Park, S., Kim, J., Kwon, O., Go, Y.-H., Jin, Y., Kim, W., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120295 · Cited by 26
Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1
Marsh, S., Hanson, B., Wood, M. J. A., Varela, M. A., & Roberts, T. C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.005 · Cited by 29
Romito, M., Juillerat, A., Kok, Y. L., Hildenbeutel, M., Rhiel, M., Andrieux, G., Geiger, J. P., Rudolph, C., Mussolino, C., Duclert, A., et al. (2020) · Biotechnology Journal · doi:10.1002/biot.202000023 · Cited by 27
Numan, M., Khan, A. L., Asaf, S., Salehin, M., Beyene, G., Tadele, Z., & Ligaba‐Osena, A. (2021) · Plants · doi:10.3390/plants10040628 · Cited by 26
Targeting Specificity of the CRISPR/Cas9 System
Tasan, I., & Zhao, H. (2017) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00270 · Cited by 26
Quadruple pegRNA enables programmable and efficient large genomic insertion
Shi, Y.-J., Ding, Z.-Y., Wu, Y., He, Z., Zhang, Y., Zhang, Y.-L., Zhang, Y.-M., Huang, X., Yin, H., & Zhang, Y. (2026) · Nature · doi:10.1038/s41586-026-10395-w · Cited by 25
Therapeutic genome engineering via CRISPR ‐Cas systems
Moreno, A. M., & Mali, P. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1380 · Cited by 25
Lin, L., Petersen, T. S., Jensen, K. T., Bolund, L., Kühn, R., & Luo, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.02.024 · Cited by 25
Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease
Baker, C. M., & Hayden, M. S. (2020) · F1000Research · doi:10.12688/f1000research.23185.1 · Cited by 26
Smith, R. H., Chen, Y.-C., Seifuddin, F., Hupalo, D. N., Alba, C., Reger, R. N., Tian, X., Araki, D., Dalgard, C. L., Childs, R. W., et al. (2020) · Genes · doi:10.3390/genes11121501 · Cited by 26
Engineered dual selection for directed evolution of SpCas9 PAM specificity
Goldberg, G. W., Spencer, J. M., Giganti, D. O., Camellato, B. R., Agmon, N., Ichikawa, D. M., Boeke, J. D., & Noyes, M. B. (2021) · Nature Communications · doi:10.1038/s41467-020-20650-x · Cited by 29
Porcine germline genome engineering
Yang, L., Church, G. M., Zhao, H., Huang, L., Gao, Y., Wei, H., & Yang, G. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004836117 · Cited by 25
Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases
Schreurs, J., Sacchetto, C., Colpaert, R. M. W., Vitiello, L., Rampazzo, A., & Calore, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010985 · Cited by 25
Nonclinical safety assessment of engineered T cell therapies
Lebrec, H. N., Maier, C. C., Maki, K., Ponce, R. A., Shenton, J. M., & Green, S. (2021) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2021.105064 · Cited by 25
Subburaj, S., Zanatta, C. B., Nunn, J. A. L., Hoepers, A. M., Nodari, R. O., & Agapito-Tenfen, S. Z. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.939997 · Cited by 25
Escobar, M., Li, J., Patel, A., Liu, S., Xu, Q., & Hilton, I. B. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00156 · Cited by 25
PEAC-seq adopts Prime Editor to detect CRISPR off-target and DNA translocation
Yu, Z., Lu, Z., Li, J., Wang, Y., Wu, P., Li, Y., Zhou, Y., Li, B., Zhang, H., Liu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35086-8 · Cited by 25
Transformer-based anti-noise models for CRISPR-Cas9 off-target activities prediction
Guan, Z., & Jiang, Z. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad127 · Cited by 27
Massively parallel CRISPR off-target detection enables rapid off-target prediction model building
Tian, R., Cao, C., He, D., Dong, D., Sun, L., Liu, J., Chen, Y., Wang, Y., Huang, Z., Li, L., et al. (2023) · Med · doi:10.1016/j.medj.2023.05.005 · Cited by 25
Metadata
- Authors
- Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., Aryee, M. J., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Tsai, Shengdar Q
- Joung, J Keith
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2014-12-16
- Volume
- 33
- Issue
- 2
- Pages
- 187-197
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4320685
- OpenAlex
- W2003797386
- Cited by
- 2,268
- References
- 39
- Citations by year
- 2026: 189 · 2025: 211 · 2024: 196 · 2023: 191 · 2022: 208 · 2021: 211 · 2020: 231 · 2019: 186 · 2018: 187 · 2017: 177 · 2016: 172 · 2015: 105 · 2014: 1
- FWCI
- 62.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM088040, F32GM105189)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR063070)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- GUIDE-seq, CRISPR-Cas nucleases, off-target cleavage, DNA double-strand breaks, genome-wide characterization, genome editing safety
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Cell Line, Humans, Oligodeoxyribonucleotides, Genome, Human, RNA Editing, DNA Breaks, Double-Stranded, High-Throughput Nucleotide Sequencing, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
